A UC Berkeley team demonstrated that combining dichloroacetate (DCA), metformin, and a 10-fold reduced dose of Navitoclax (ABT-263) — branded as 'DMA' — selectively eliminates both senescent and cancer cells by exploiting their shared metabolic vulnerability: defective ATP production. In vitro, DMA ablated multiple senescent and malignant cell types while sparing healthy human cells. In aged mice, acute DMA administration improved functional performance, and prolonged dosing extended lifespan, largely sidestepping the dose-dependent thrombocytopenia that has stalled Navitoclax's clinical adoption.
The conceptual elegance here is notable: senescent and cancer cells converge on dysfunctional mitochondrial metabolism, and DMA weaponizes that shared weakness simultaneously. Metformin inhibits Complex I; DCA blocks pyruvate dehydrogenase kinase, forcing oxidative metabolism that stressed cells cannot handle; low-dose Navitoclax then tips them into apoptosis. This multi-target, metabolic-priming approach could represent a genuine advance over single-agent senolytics like dasatinib-plus-quercetin, which show more modest in vivo longevity effects.
Critical caveats remain substantial: mouse lifespan data rarely translates linearly to humans, DCA carries its own neurotoxicity concerns at chronic doses, and the mechanism driving in vivo lifespan extension is incompletely characterized. This is original data, not a review, and the findings are genuinely provocative rather than merely incremental — though human trials will be the real test of whether DMA's selectivity holds at scale.